The Autism Spectrum Disorder (ASD) drugs in development market research report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Autism Spectrum Disorder (ASD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Autism Spectrum Disorder (ASD) and features dormant and discontinued products.
GlobalData tracks 139 drugs in development for Autism Spectrum Disorder (ASD) by 104 companies/universities/institutes. The top development phase for Autism Spectrum Disorder (ASD) is preclinical with 74 drugs in that stage. The Autism Spectrum Disorder (ASD) pipeline has 132 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Autism Spectrum Disorder (ASD) pipeline products market are: Parkure, Stalicla and Nova Mentis BioTech.
The key targets in the Autism Spectrum Disorder (ASD) pipeline products market include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), and Cannabinoid Receptor 2 (CB2 or CX5 or CNR2).
The key mechanisms of action in the Autism Spectrum Disorder (ASD) pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with seven drugs in Phase III. The Autism Spectrum Disorder (ASD) pipeline products include ten routes of administration with the top ROA being Oral and 12 key molecule types in the Autism Spectrum Disorder (ASD) pipeline products market including Small Molecule, and Biologic.
Autism Spectrum Disorder (ASD) overview
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication and social skills, promoting better adaptation to daily life. While the exact cause is unclear, a combination of genetic and environmental factors is believed to contribute. Embracing neurodiversity fosters acceptance and understanding of individuals with ASD.
For a complete picture of Autism Spectrum Disorder (ASD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
